Clinical Trials Sponsored by CLL Consortium

Total 1952 results

Pfizer
Academic GI Cancer Consortium (AGICC)

Terminated

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Metastatic Cancer Pancreas

United States
Örebro University, Sweden
Fibebiotics consortium (EU)

Completed

Prebiotic Supplementation and Intestinal Barrier Function in Elderly: a RCT

Aged | Prebiotics

Sweden
Canadian Urology Research Consortium
OICR; Eigen

Unknown

Active Surveillance Magnetic Resonance Imaging Study (ASIST)

Prostate Cancer

Canada
Chronic Lymphocytic Leukemia Research Consortium
Bayer

Unknown

Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy (CRC005)

B-Cell Chronic Lymphocytic Leukemia

United States
Attenuon
Prostate Cancer Clinical Trials Consortium

Unknown

Study of ATN-224 in Patients With Prostate Cancer

Prostate Cancer

United States
CSL Behring

Recruiting

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

Hereditary Angioedema (HAE)

United States, Israel
CSL Behring

Recruiting

Hizentra® in Inflammatory Neuropathies - pHeNIx Study (pHeNIx)

Chronic Inflammatory Demyelinating Polyneuropathy

France
CSL Behring

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (RECLAIIM)

Dermatomyositis

United States, Argentina, Belgium, France, Germany, Hungary, Italy, Japan, Mexico, Poland, Russian Federation, Spain, Switzerland, Ukraine
CSL Behring

Active, not recruiting

Respreeza® Self-administration and Learning Program (AmAREtTI Study) (AmAREtTI)

Alpha-1 Antitrypsin Deficiency

France
CSL Behring

Active, not recruiting

HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients

Hemophilia B

United States, Belgium, Netherlands, Denmark, Germany, Ireland, Sweden, United Kingdom
CSL Behring

Completed

Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)

Noncystic Fibrosis Bronchiectasis (NCFB)

United Kingdom, Germany
CSL Behring

Completed

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

Diabetic Kidney Disease (DKD)

United States, Australia, New Zealand, Puerto Rico, Canada, Israel
CSL Behring

Terminated

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Immune Complex-mediated Autoimmune Diseases

United Kingdom
CPL Associates

Completed

Characterization of Metabolic Biomarkers in Varying Subjects

Obesity | Type 2 Diabetes

United States
CSL Behring

Withdrawn

Fibrinogen Concentrate (Human) - Efficacy and Safety Study

Afibrinogenemia | Hypofibrinogenemia | Fibrinogen Deficiency
CSL Behring

Completed

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

Healthy Volunteers

United States
CSL Behring

Completed

Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B

Hemophilia B

Germany, Denmark, Netherlands
CSL Behring

Completed

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Coronavirus Disease 2019 (COVID-19)

United States
CSL Behring

Completed

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

Rheumatoid Arthritis

Italy, Japan, Taiwan, United States, Spain, Argentina, Belgium, Germany, Korea, Republic of, Czechia, Russian Federation, France, Mexico, Poland, South Africa, Hungary, Brazil, Canada, Netherlands
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
CSL Behring

Completed

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A | Severe Hemophilia A

United States, Australia, Austria, Canada, Czechia, France, Georgia, Germany, Hungary, Ireland, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, South Africa, Spain, Switzerland, Thailand, Ukraine, United...
CSL Behring

Terminated

Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults

Healthy

United Kingdom, Netherlands
CSL Behring

Completed

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Primary Immunodeficiency

United States, Canada
CSL Behring

Withdrawn

A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

PICC-associated Thrombosis
CSL Behring

Terminated

Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors

Hemophilia A With Inhibitors | Hemophilia B With Inhibitors

Georgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
CSL Behring

Completed

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Germany, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
CSL Behring

Completed

Study of Voncento® in Subjects With Von Willebrand Disease

Von Willebrand Disease

Poland, Germany, Austria, Greece, United Kingdom
CSL Behring

Terminated

Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development

Hemophilia A

Russian Federation, Germany, Italy, Austria, Greece
CSL Behring

Completed

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Congenital Hemophilia A

United States, Austria, Germany, Malaysia, Netherlands, Philippines, Ukraine, Romania, Spain, Australia, France, Georgia, Italy, Lebanon, Poland, Portugal, Switzerland, Thailand, Turkey
CSL Behring

Completed

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Hemophilia A

United States, Australia, Austria, Canada, Czech Republic, Germany, Hungary, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
CSL Limited

Completed

Ig NextGen 10% in Idiopathic Thrombocytopenic Purpura (ITP) Patients

Idiopathic Thrombocytopenic Purpura (ITP)

Australia
CSL Behring

Completed

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Hemophilia B

Germany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
CSL Behring

Completed

Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects

Acute Major Bleeding | Reversal of Coagulopathy

Japan
CSL Behring

Completed

A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

Serbia, Romania, Bulgaria
CSL Behring

Completed

Quality of Life Study of Helixate NexGen

Hemophilia A

Austria, Belgium, France, Germany, Italy, Spain, Switzerland
CSL Limited

Completed

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

Stable Atherothrombotic Disease

United States
CSL Behring

Completed

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

Blood Coagulation Disorders | Acute Major Bleeding

United States, Belarus, Bulgaria, Romania, Russian Federation, Ukraine
CSL Behring

Completed

Haemocomplettan® P During Aortic Replacement

Aortic Aneurysm

Germany
CSL Behring

Completed

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

Primary Immune Deficiency

United States
CSL Limited

Completed

Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

Primary Immune Deficiency (PID)

Australia
CSL Behring

Completed

Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

Common Variable Immunodeficiency | Agammaglobulinemia | IgG Deficiency
CSL Limited

Completed

A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers

Healthy

Australia
CSL Behring

Completed

Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B

Hemophilia B

Spain, Italy, France, Germany, Austria, Israel
CSL Behring

Completed

A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency

Factor XIII Deficiency

United States, Spain
CSL Behring

Completed

Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10

Immune Thrombocytopenic Purpura

Poland, Ukraine, Germany, Russian Federation, Italy, United Kingdom
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

Common Variable Immunodeficiency | X-linked Agammaglobulinemia | Autosomal Recessive Agammaglobulinemia

Germany, United Kingdom, France, Italy, Poland, Romania, Spain, Sweden, Switzerland
CSL Behring

Completed

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)

Blood Coagulation Disorders | Blood Platelet Disorders | Hematologic Disease | Von Willebrand Disease

United States
CSL Behring

Completed

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

Common Variable Immunodeficiency | Agammaglobulinemia | IgG Deficiency
CSL Limited

Completed

Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Australia
Cell Genesys

Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)

Prostate Cancer

Clinical Trials Sponsored by CLL Consortium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations